Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | SLC5A2 | P31639 | 10/20 | 0.48 |
| ▸ | SLC5A1 | P13866 | 8/20 | 0.48 |
| ▸ | TYR | P14679 | 2/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27084753 | 0.93 | TYR (0.50) | ATMSLC5A2SLC5A1TYRCA12 | |
| SCHEMBL27084910 | 0.92 | ATM (0.48) | ATMSLC5A2SLC5A1TYRHTR1D | |
| SCHEMBL27085008 | 0.91 | ATM (0.48) | ATMSLC5A2SLC5A1TYRHTR1D | |
| SCHEMBL27084741 | 0.89 | HTR1D (0.56) | ATMSLC5A2SLC5A1TYRHTR1D | |
| SCHEMBL26790014 | 0.89 | HTR1D (0.56) | ATMSLC5A2SLC5A1TYRHTR1D | |
| SCHEMBL26790992 | 0.89 | HTR1D (0.56) | ATMSLC5A2SLC5A1TYRHTR1D | |
| SCHEMBL27085137 | 0.89 | HTR1D (0.46) | HTR1DHTR1BCA12CA9 | |
| SCHEMBL27084663 | 0.88 | HTR1A (0.57) | ATMSLC5A2SLC5A1TYRHTR1D | |
| SCHEMBL27084964 | 0.87 | HTR1D (0.52) | ATMSLC5A2SLC5A1TYRHTR1D | |
| SCHEMBL27085283 | 0.87 | HTR2A (0.52) | ATMSLC5A2SLC5A1TYRHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043382-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | COMPASS PATHFINDER LIMITED (GB) | 2024-02-08 | — | — | US | disclosed |
| CN-117120415-A | Modified indole alkaloids for therapeutic use | 指南针探路者有限公司 | 2023-11-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043382-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | INMT, AANAT, HNMT | ATM 3022/4885SLC5A2 3921/4885SLC5A1 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.